What is Remynd?
Remynd is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for conditions such as Alzheimer's disease, diabetes, and epilepsy, all stemming from cellular dysfunction. The company leverages a proprietary drug discovery platform designed to identify novel mechanisms of action, therapeutic targets, and first-in-class small molecules. Its most advanced program, ReS19-T, an investigational compound for Alzheimer's, has entered clinical trials. Remynd is also developing ReS39, a treatment for diabetes aimed at enhancing endogenous insulin production. The company's research extends to other major health challenges, with a focus on mitochondrial dysfunction in central nervous system (CNS) disorders. Additionally, Remynd operates a Contract Research Organization (CRO) specializing in CNS disorders, serving a global clientele.
How much funding has Remynd raised?
Remynd has raised a total of $29.2M across 1 funding round:
Series B
$29.2M
Series B (2021): $29.2M with participation from BNP Paribas Fortis, FPIM, Korys Investments, KU Leuven, and PMV Groupe
Key Investors in Remynd
BNP Paribas Fortis
BNP Paribas Fortis, a prominent Belgian banking institution, provides a range of financial services and solutions, indicating a strategic financial partnership for Remynd's growth.
FPIM
FPIM, a key financial backer, is participating in Remynd's funding round, signaling support for the company's therapeutic development initiatives.
Korys Investments
Korys Investments, a significant investor, is contributing capital to Remynd, likely focusing on the company's innovative approach to treating complex diseases.
What's next for Remynd?
With a substantial enterprise-level funding round, Remynd is poised to accelerate the development and clinical progression of its lead candidates, ReS19-T and ReS39. The strategic investment will likely fuel further research into its pipeline of treatments for neurodegenerative diseases and metabolic disorders. Expansion of its proprietary drug discovery platform and enhancement of its CRO services are also probable strategic objectives. This significant capital infusion positions Remynd to navigate the complexities of late-stage clinical development and regulatory pathways, aiming to bring its novel therapies to market and address unmet medical needs.
See full Remynd company page
